Citadel Advisors’s Altimmune ALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.38M | Sell |
448,873
-889,054
| -66% | -$3.77M | ﹤0.01% | 6905 |
|
|
2025
Q4 | $4.83M | Buy |
1,337,927
+55,913
| +4% | +$244K | ﹤0.01% | 4337 |
|
|
2025
Q3 | $4.83M | Buy |
1,282,014
+758,553
| +145% | +$2.93M | ﹤0.01% | 4420 |
|
|
2025
Q2 | $2.03M | Buy |
+523,461
| New | +$2.83M | ﹤0.01% | 5680 |
|
|
2025
Q1 | – | Sell |
-675,044
| Closed | -$4.28M | – | 14401 |
|
|
2024
Q4 | $4.87M | Buy |
675,044
+247,457
| +58% | +$1.89M | ﹤0.01% | 4015 |
|
|
2024
Q3 | $2.63M | Buy |
427,587
+426,566
| +41,779% | +$2.89M | ﹤0.01% | 5020 |
|
|
2024
Q2 | $6.79K | Sell |
1,021
-75,046
| -99% | -$554K | ﹤0.01% | 13303 |
|
|
2024
Q1 | $774K | Buy |
+76,067
| New | +$774K | ﹤0.01% | 7462 |
|
|
2023
Q4 | – | Sell |
-119,404
| Closed | -$499K | – | 14209 |
|
|
2023
Q3 | $310K | Sell |
119,404
-211,425
| -64% | -$607K | ﹤0.01% | 9099 |
|
|
2023
Q2 | $1.17M | Sell |
330,829
-1,713,656
| -84% | -$7.69M | ﹤0.01% | 6137 |
|
|
2023
Q1 | $8.63M | Buy |
2,044,485
+885,024
| +76% | +$10.5M | ﹤0.01% | 2997 |
|
|
2022
Q4 | $19.1M | Buy |
1,159,461
+1,030,210
| +797% | +$11.6M | ﹤0.01% | 2016 |
|
|
2022
Q3 | $1.65M | Sell |
129,251
-1,018,607
| -89% | -$15M | ﹤0.01% | 5955 |
|
|
2022
Q2 | $13.4M | Buy |
1,147,858
+23,451
| +2% | +$145K | ﹤0.01% | 2306 |
|
|
2022
Q1 | $6.85M | Buy |
1,124,407
+86,453
| +8% | +$637K | ﹤0.01% | 3588 |
|
|
2021
Q4 | $9.51M | Sell |
1,037,954
-51,898
| -5% | -$551K | ﹤0.01% | 3162 |
|
|
2021
Q3 | $12.3M | Sell |
1,089,852
-201,013
| -16% | -$2.44M | ﹤0.01% | 2717 |
|
|
2021
Q2 | $12.7M | Buy |
1,290,865
+160,606
| +14% | +$2.2M | ﹤0.01% | 2719 |
|
|
2021
Q1 | $16M | Buy |
1,130,259
+20,415
| +2% | +$330K | ﹤0.01% | 2270 |
|
|
2020
Q4 | $12.5M | Buy |
1,109,844
+664,907
| +149% | +$7.83M | ﹤0.01% | 2353 |
|
|
2020
Q3 | $5.87M | Sell |
444,937
-123,960
| -22% | -$2.48M | ﹤0.01% | 2925 |
|
|
2020
Q2 | $6.09M | Buy |
+568,897
| New | +$3.13M | ﹤0.01% | 2814 |
|
|
2020
Q1 | – | Sell |
-24,319
| Closed | -$55.9K | – | 9539 |
|
|
2019
Q4 | $46K | Buy |
24,319
+7,295
| +43% | +$13.5K | ﹤0.01% | 8775 |
|
|
2019
Q3 | $33K | Sell |
17,024
-7,790
| -31% | -$17.3K | ﹤0.01% | 8820 |
|
|
2019
Q2 | $59K | Buy |
24,814
+11,733
| +90% | +$31.4K | ﹤0.01% | 8675 |
|
|
2019
Q1 | $38K | Buy |
+13,081
| New | +$39K | ﹤0.01% | 8917 |
|
|
2018
Q3 | – | Sell |
-1,664
| Closed | -$22K | – | 9160 |
|
|
2018
Q2 | $22K | Buy |
+1,664
| New | +$32.8K | ﹤0.01% | 8622 |
|
|
2017
Q2 | – | Sell |
-904
| Closed | -$220K | – | 7421 |
|
|
2017
Q1 | $220K | Buy |
+904
| New | +$484K | ﹤0.01% | 6357 |
|
|
2016
Q4 | – | Sell |
-42
| Closed | -$37.6K | – | 7195 |
|
|
2016
Q3 | $37K | Sell |
42
-124
| -75% | -$97.3K | ﹤0.01% | 6911 |
|
|
2016
Q2 | $121K | Buy |
166
+23
| +16% | +$15.7K | ﹤0.01% | 6110 |
|
|
2016
Q1 | $81K | Buy |
+143
| New | +$73.2K | ﹤0.01% | 6105 |
|
|
2015
Q1 | – | Sell |
-54
| Closed | -$30K | – | 8483 |
|
|
2014
Q4 | $30K | Sell |
54
-1
| -2% | -$513 | ﹤0.01% | 7545 |
|
|
2014
Q3 | $30K | Buy |
55
+38
| +224% | +$19.9K | ﹤0.01% | 7211 |
|
|
2014
Q2 | $7K | Sell |
17
-89
| -84% | -$40.2K | ﹤0.01% | 7658 |
|
|
2014
Q1 | $58K | Buy |
+106
| New | +$61.9K | ﹤0.01% | 6645 |
|
Other funds holding ALT
VCM
VPM
N
Citadel Advisors's ALT Position: Q1 2026 in Review
Citadel Advisors reduced its Altimmune (ALT) stake by 66% in Q1 2026, selling an estimated $3.77M and leaving 448,873 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #6905.
Citadel Advisors first reported a position in ALT in Q1 2014 and has held it in 35 quarters since. The position peaked at $19.1M in Q4 2022. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.
- Citadel Advisors held 448,873 shares of Altimmune worth $1.38M as of Q1 2026.
- Citadel Advisors sold 889,054 Altimmune shares in Q1 2026, an estimated $3.77M.
- Altimmune made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6905 holding.
- Citadel Advisors first reported a position in Altimmune in Q1 2014 and has held it in 35 quarters since.
- Citadel Advisors's Altimmune position peaked at $19.1M in Q4 2022.
- 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.